[Insulin therapy in type 1 diabetes].
Insulin therapy of type 1 diabetic patients aims at insuring both a good quality of life, especially avoiding severe hypoglycaemia, and a good metabolic control, more particularly to prevent diabetic complications. The most appropriate insulin scheme comprises the injection of a short-acting insulin before each meal, to control postprandial hyperglycaemia, and one (or possibly two) injection of a long-acting insulin, to maintain adequate plasma glucose levels between meals and at night. Insulin analogues, with ultrashort activity (insulin lispro or aspart) or with a basal activity (insulin glargine or detemir), offer some pharmacokinetic advantages when compared to conventional insulins. What ever the insulin scheme and the type of insulin used, it is crucial that the diabetic patient benefits of a specific extensive educational programme and practices regularly home blood glucose monitoring, in order to adjust him or herself the antidiabetic treatment to reach near normoglycaemia. Functional insulin therapy may be part of this strategy.
Philips
J C
JC
Service de Diabétologie, Nutrition et Maladies Métaboliques, Département de Médecine, CHU de Liège.
Radermecker
R P
RP
D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010353:Patient Education as Topic; D019518:Postprandial Period
D007004:Hypoglycemic Agents; D007328:Insulin